Meng-qing Wang , Bin Wang , Xu Yang , Qi-chun Zhang , Xu-yang Wang , Yin-feng Dong
{"title":"ClC-3-depedent polarization of microglia protects against cerebral ischemic injury in mice","authors":"Meng-qing Wang , Bin Wang , Xu Yang , Qi-chun Zhang , Xu-yang Wang , Yin-feng Dong","doi":"10.1016/j.intimp.2025.114618","DOIUrl":null,"url":null,"abstract":"<div><div>Polarization of microglia has attracted great attention in ischemic stroke. Emerging evidence suggests that chloride channel 3 (ClC-3) is involved in inflammatory responses and stroke. However, the link between ClC-3 and polarization of microglia in ischemic stroke remains unclear. Herein, we found both cerebral ischemia and oxygen-glucose deprivation (OGD) induced a significant upregulation of ClC-3 in microglia. While knockdown of ClC-3 markedly increased nuclear factor kappa B (NF-κB) and CD86, and decreased CD206 in BV-2 cells under OGD conditions, facilitating them to shift into a M1-like phenotype. Furthermore, ClC-3 knockout significantly aggravated infarct volume and neurological deficits, accompanied by increased activated microglia in the peri-infarct area 1 day after cerebral ischemia. By contrast, ClC-3 overexpression obviously suppressed nuclear translocation of NF-κB, decreased OGD-induced elevated mRNA levels of TNF-α, IL-1β and IL-10, and enhanced M2-like markers (Arg1, CD206, and TREM2) in microglia, leading to alleviated infarct volume and neurological deficits. While ClC-3 overexpression could not reverse a transformation from M1-like phenotype to M2-like polarization in presence of lipopolysaccharide (LPS) and interferon gamma (IFNγ) treatment for 24 h. Collectively, our findings indicate that ClC-3-dependent polarization of microglia is critically important for protecting against cerebral ischemia injury, suggesting ClC-3 is a promising therapeutic target for ischemic stroke.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"155 ","pages":"Article 114618"},"PeriodicalIF":4.8000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925006083","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Polarization of microglia has attracted great attention in ischemic stroke. Emerging evidence suggests that chloride channel 3 (ClC-3) is involved in inflammatory responses and stroke. However, the link between ClC-3 and polarization of microglia in ischemic stroke remains unclear. Herein, we found both cerebral ischemia and oxygen-glucose deprivation (OGD) induced a significant upregulation of ClC-3 in microglia. While knockdown of ClC-3 markedly increased nuclear factor kappa B (NF-κB) and CD86, and decreased CD206 in BV-2 cells under OGD conditions, facilitating them to shift into a M1-like phenotype. Furthermore, ClC-3 knockout significantly aggravated infarct volume and neurological deficits, accompanied by increased activated microglia in the peri-infarct area 1 day after cerebral ischemia. By contrast, ClC-3 overexpression obviously suppressed nuclear translocation of NF-κB, decreased OGD-induced elevated mRNA levels of TNF-α, IL-1β and IL-10, and enhanced M2-like markers (Arg1, CD206, and TREM2) in microglia, leading to alleviated infarct volume and neurological deficits. While ClC-3 overexpression could not reverse a transformation from M1-like phenotype to M2-like polarization in presence of lipopolysaccharide (LPS) and interferon gamma (IFNγ) treatment for 24 h. Collectively, our findings indicate that ClC-3-dependent polarization of microglia is critically important for protecting against cerebral ischemia injury, suggesting ClC-3 is a promising therapeutic target for ischemic stroke.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.